ReviewLife (Basel, Switzerland)2022

α2-Antiplasmin as a Potential Therapeutic Target for Systemic Sclerosis.

Yosuke Kanno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.